See also separate profile for ivacaftor.
- Trade Name: Orkambi (Vertex)
- Indications: Cystic fibrosis in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene
- Class: CFTR potentiator, CYP3A4 inducer
- Half-life: 26 hours
- FDA Approval Date: 07/02/2015
- Clinically important, potentially hazardous interactions with:
Rifampin, St John's Wort
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of lumacaftor/ivacaftor in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
